These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 7856434)

  • 1. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L; Galbignani E
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
    Akerlund M; Almström E; Högstedt S; Nabrink M
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
    Mastorakos G; Koliopoulos C; Creatsas G
    Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
    Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
    Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
    Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
    Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
    Porcile A; Gallardo E
    Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination.
    Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
    Acta Obstet Gynecol Scand; 1985; 64(3):203-7. PubMed ID: 3160212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
    Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
    Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Trpković D; Balint-Perić L
    Gynecol Endocrinol; 1990 Sep; 4(3):157-68. PubMed ID: 2284980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.
    Villaseca P; Hormaza P; Cárdenas I; Oestreicher E; Arteaga E
    Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):155-65. PubMed ID: 15697105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
    Oyelola OO
    Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.
    Adeniji AA; Essah PA; Nestler JE; Cheang KI
    J Womens Health (Larchmt); 2016 Jun; 25(6):638-45. PubMed ID: 26871978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.